000120637 001__ 120637
000120637 005__ 20240228145457.0
000120637 0247_ $$2doi$$a10.18632/oncotarget.15934
000120637 0247_ $$2pmid$$apmid:28460484
000120637 0247_ $$2pmc$$apmc:PMC5432336
000120637 0247_ $$2altmetric$$aaltmetric:17076713
000120637 037__ $$aDKFZ-2017-01065
000120637 041__ $$aeng
000120637 082__ $$a610
000120637 1001_ $$aWiese, Maria$$b0
000120637 245__ $$aThe β-catenin/CBP-antagonist ICG-001 inhibits pediatric glioma tumorigenicity in a Wnt-independent manner.
000120637 260__ $$a[S.l.]$$bImpact Journals LLC$$c2017
000120637 3367_ $$2DRIVER$$aarticle
000120637 3367_ $$2DataCite$$aOutput Types/Journal article
000120637 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1511260993_9921
000120637 3367_ $$2BibTeX$$aARTICLE
000120637 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000120637 3367_ $$00$$2EndNote$$aJournal Article
000120637 520__ $$aPediatric high-grade gliomas (pedHGG) belong to the most aggressive cancers in children with a poor prognosis due to a lack of efficient therapeutic strategies. The β-catenin/Wnt-signaling pathway was shown to hold promising potential as a treatment target in adult high-grade gliomas by abrogating tumor cell invasion and the acquisition of stem cell-like characteristics. Since pedHGG differ from their adult counterparts in genetically and biologically we aimed to investigate the effects of β-catenin/Wnt-signaling pathway-inhibition by the β-catenin/CBP antagonist ICG-001 in pedHGG cell lines. In contrast to adult HGG, pedHGG cells displayed minimal detectable canonical Wnt-signaling activity. Nevertheless, low doses of ICG-001 inhibited cell migration/invasion, tumorsphere- and colony formation, proliferation in vitro as well as tumor growth in vivo/ovo, suggesting that ICG-001 affects pedHGG tumor cell characteristics independent of β-catenin/Wnt-signaling. RNA-sequencing analyses support a Wnt/β-catenin-independent effect of ICG-001 on target gene transcription, revealing strong effects on genes involved in cellular metabolic/biosynthetic processes and cell cycle progression. Among these, high mRNA expression of cell cycle regulator JDP2 was found to confer a better prognosis for pedHGG patients. In conclusion, ICG-001 might offer an effective treatment option for pedHGG patients functioning to regulate cell phenotype and gene expression programs in absence of Wnt/β-catenin signaling-activity.
000120637 536__ $$0G:(DE-HGF)POF3-312$$a312 - Functional and structural genomics (POF3-312)$$cPOF3-312$$fPOF III$$x0
000120637 588__ $$aDataset connected to CrossRef, PubMed,
000120637 7001_ $$aWalther, Neele$$b1
000120637 7001_ $$aDiederichs, Christopher$$b2
000120637 7001_ $$aSchill, Fabian$$b3
000120637 7001_ $$aMonecke, Sebastian$$b4
000120637 7001_ $$aSalinas, Gabriela$$b5
000120637 7001_ $$0P:(DE-He78)a46a5b2a871859c8e2d63d2f8c666807$$aSturm, Dominik$$b6$$udkfz
000120637 7001_ $$0P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aPfister, Stefan$$b7$$udkfz
000120637 7001_ $$aDressel, Ralf$$b8
000120637 7001_ $$aJohnsen, Steven A$$b9
000120637 7001_ $$aKramm, Christof M$$b10
000120637 773__ $$0PERI:(DE-600)2560162-3$$a10.18632/oncotarget.15934$$gVol. 8, no. 16$$n16$$p27300-27313$$tOncoTarget$$v8$$x1949-2553$$y2017
000120637 909CO $$ooai:inrepo02.dkfz.de:120637$$pVDB
000120637 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a46a5b2a871859c8e2d63d2f8c666807$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000120637 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000120637 9131_ $$0G:(DE-HGF)POF3-312$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunctional and structural genomics$$x0
000120637 9141_ $$y2017
000120637 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bONCOTARGET : 2015
000120637 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000120637 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000120637 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000120637 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000120637 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000120637 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000120637 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000120637 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bONCOTARGET : 2015
000120637 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lPädiatrische Neuroonkologie$$x0
000120637 980__ $$ajournal
000120637 980__ $$aVDB
000120637 980__ $$aI:(DE-He78)B062-20160331
000120637 980__ $$aUNRESTRICTED